Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine
Dates
study started
estimated completion

Description

Summary

The study will evaluate the efficacy and safety of aprepitant injectable emulsion added to standard of care for hospitalized patients with COVID-19.

Official Title

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Aprepitant Injectable Emulsion in Early Hospitalized Adult Patients With COVID-19

Keywords

COVID-19 Coronavirus Aprepitant Aprepitant injectable emulsion

Eligibility

You can join if…

Open to people ages 18 years and up

  • Is hospitalized for ≤24 hours with SARS-CoV-2 infection. confirmed by polymerase chain reaction test.
  • Has oxygen saturation ≤93% by pulse oximetry on room air and requiring supplemental. oxygen but not anticipated to require mechanical ventilation within 48 hours.

You CAN'T join if...

  • Is taking high-dose hydroxychloroquine or chloroquine.
  • Is taking pimozide or strong or moderate CYP3A4 inhibitors.
  • Is currently receiving treatment with products intended to modify immune resp)onse to

COVID-19 (exception: dexamethasone, methylprednisolone, or equivalent are allowed, chemotherapy or on hemodialysis or peritoneal dialysis.

  • Has known hypersensitivity to any components of aprepitant injectable emulsion.
  • Has evidence of ARDS.
  • Is being treated with oxygen delivered by high-flow nasal cannula nonrebreather mask, noninvasive positive pressure ventilation, or ECMO.
  • Has multiple organ failure.
  • Has current confirmed Influenza A or B infection, or a a history of organ or hematologic transplant, HIV, or active hepatitis B or hepatitis C infection.

Locations

  • University of California, Irvine Medical Center accepting new patients
    Orange California 92868 United States
  • Memorial Hermann - Memorial City Medical Center accepting new patients
    Houston Texas 77024 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Heron Therapeutics
ID
NCT04470622
Phase
Phase 2
Study Type
Interventional
Last Updated